Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 560 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... February 3, 2023 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... November 5, 2021 Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 Load more HOT NEWS A More Treatable Kind of Metastatic Cancer? FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... EMA Recommends Extension of Therapeutic Indications for Olaparib 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with...
